[1] 陆伦根, 尤红, 谢渭芬, 等. 肝纤维化诊断及治疗共识(2019年版)[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2] Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China[J]. Gastroenterology, 2023,165(4):1025-1040.
[3] Zhang YN, Fowler KJ, Ozturk A, et al. Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography[J]. J Magn Reson Imaging, 2020, 51(1): 25-42.
[4] Im WH, Song JS, Jang W. Noninvasive staging of liver fibrosis: review of current quantitative CT and MRI-based techniques[J]. Abdom Radiol, 2022, 47(9): 3051-3067.
[5] Li S, Sun X, Chen M, et al. Liver fibrosis conventional and molecular imaging diagnosis update[J]. J liver, 2019, 8(1): 236.
[6] Jayaswal ANA, Levick C, Selvaraj EA, et al. Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease[J]. Liver Int, 2020, 40(12): 3071-3082.
[7] Montesi SB, Désogère P, Fuchs BC, et al. Molecular imaging of fibrosis: recent advances and future directions[J]. J Clin Invest, 2019, 129(1): 24-33.
[8] Castera L. Non-invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics[J]. Liver Int, 2020, 40(S1): 77-81.
[9] Tsochatzis EA. Screening for liver fibrosis-sequential non-invasive testing works best[J]. J Hepatol, 2023, 79(2): 263-265.
[10] Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2019, 71(2): 371-378.
[11] Berzigotti A, Tsochatzis E, Boursier J, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update[J]. J Hepatol, 2021, 75(3): 659-689.
[12] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835.
[13] Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease[J]. J Hepatol, 2023, 79(2): 277-286.
[14] Yao M, Wang L, Leung PSC, et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review[J]. Clin Rev Allergy Immunol, 2018, 54(2): 282-294.
[15] Liu L, Al-Dhamin Z, Yuan X, et al. Plasma Golgi protein 73 levels predict prognosis of HCV-related hepatic fibrosis[J]. Histol Histopathol, 2020, 35(11): 1309-1318.
[16] Cao Z, Li Z, Wang H, et al. Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection[J]. Liver Int, 2017, 37(11): 1612-1621.
[17] 姚明解, 王雷婕, 关贵文, 等. 血清高尔基体蛋白73在辅助诊断慢性乙型肝炎患者中度以上肝损伤中的应用[J]. 临床肝胆病杂志, 2018, 34(4): 755-759.
[18] Smirne C, Rigamonti C, De Benedittis C, et al. Gas6/TAM signaling components as novel biomarkers of liver fibrosis[J]. Dis Markers, 2019, 2019: e2304931.
[19] Caussy C, Chuang JC, Billin A, et al. Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis[J]. Ther Adv Gastroenterol, 2020, 13: 1756284820923904.
[20] Kozumi K, Kodama T, Murai H, et al. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis[J]. Hepatology, 2021, 74(5): 2452-2466. |
